| Preface to the Second Edition |
|
iii | |
| Preface to the First Edition |
|
v | |
| Contributors |
|
xv | |
|
PART I: METHODS OF ENCAPSULATION AND ADVANCES IN PRODUCTION TECHNOLOGY |
|
|
|
Biodegradable Microspheres: Advances in Production Technology |
|
|
1 | (54) |
|
|
|
|
|
|
|
|
|
1 | (1) |
|
Techniques Using Organic Solvents |
|
|
2 | (6) |
|
Techniques Without Organic Solvents |
|
|
8 | (33) |
|
|
|
41 | (14) |
|
Advances in the Technology for Controlled-Release Pesticide Formulations |
|
|
55 | (24) |
|
|
|
|
|
|
|
55 | (4) |
|
Standard Microencapsulation Processes for Pesticides |
|
|
59 | (8) |
|
Advances in Encapsulation Technologies |
|
|
67 | (4) |
|
|
|
71 | (4) |
|
|
|
75 | (1) |
|
|
|
75 | (1) |
|
|
|
76 | (3) |
|
Multiparticulate Pulsatile Drug Delivery Systems |
|
|
79 | (20) |
|
|
|
|
|
|
|
79 | (4) |
|
|
|
83 | (1) |
|
|
|
84 | (2) |
|
Time-Controlled Pulsatile Systems |
|
|
86 | (1) |
|
|
|
87 | (7) |
|
|
|
94 | (1) |
|
|
|
94 | (5) |
|
Microencapsulation Techniques for Parenteral Depot Systems and Their Application in the Pharmaceutical Industry |
|
|
99 | (24) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99 | (1) |
|
|
|
100 | (3) |
|
Phase Separation and Coacervation |
|
|
103 | (3) |
|
W/O/W-Double Emulsion Technique |
|
|
106 | (7) |
|
|
|
113 | (5) |
|
|
|
118 | (1) |
|
|
|
118 | (5) |
|
Coupling Methods to Obtain Ligand-Targeted Liposomes and Nanoparticles |
|
|
123 | (26) |
|
|
|
|
|
|
|
|
|
|
|
123 | (1) |
|
Liposomal Modification Techniques |
|
|
124 | (14) |
|
Labeling Polymeric Nanoparticles with Ligands |
|
|
138 | (3) |
|
How to Choose the Coupling Method |
|
|
141 | (1) |
|
|
|
142 | (1) |
|
|
|
142 | (7) |
|
Industrial Technologies and Scale-Up |
|
|
149 | (34) |
|
|
|
|
|
|
|
|
|
149 | (3) |
|
|
|
152 | (12) |
|
Scale-Up Approach: The Case of Emulsification |
|
|
164 | (3) |
|
|
|
167 | (11) |
|
|
|
178 | (1) |
|
|
|
178 | (1) |
|
|
|
179 | (4) |
|
PART II: EVALUATION AND CHARACTERIZATION OF MICRO- AND NANOPARTICULATE DRUG DELIVERY SYSTEMS |
|
|
|
Drug Release from Microparticulate Systems |
|
|
183 | (30) |
|
|
|
|
|
|
|
183 | (1) |
|
Measurement of Drug Release |
|
|
183 | (3) |
|
Mechanisms of Drug Release |
|
|
186 | (2) |
|
Drug Release Kinetic Models |
|
|
188 | (10) |
|
Empirical Models and Comparison of Drug Release Profiles |
|
|
198 | (5) |
|
In Vitro-In Vivo Correlation |
|
|
203 | (1) |
|
|
|
204 | (1) |
|
|
|
205 | (8) |
|
Manufacture, Characterization, and Applications of Solid Lipid Nanoparticles as Drug Delivery Systems |
|
|
213 | (56) |
|
|
|
|
|
Introduction: The Rationale of Using Biodegradable, Nanoparticulate Solid Lipids in Drug Delivery |
|
|
213 | (3) |
|
Manufacturing Methods for Lipid Nanoparticle Suspensions |
|
|
216 | (14) |
|
Physicochemical Characterization of Colloidal Lipid Suspensions and Nanoparticles |
|
|
230 | (12) |
|
Applications in Drug Delivery |
|
|
242 | (13) |
|
|
|
255 | (2) |
|
|
|
257 | (12) |
|
Amphiphilic Cyclodextrins and Microencapsulation |
|
|
269 | (28) |
|
|
|
|
|
|
|
|
|
|
|
|
|
269 | (1) |
|
Cyclodextrins and Derivatives |
|
|
270 | (8) |
|
Amphiphilic Cyclodextrin Nanoparticles |
|
|
278 | (13) |
|
|
|
291 | (1) |
|
|
|
291 | (6) |
|
Lipospheres for Controlled Delivery of Substances |
|
|
297 | (20) |
|
|
|
|
|
297 | (1) |
|
Preparation of Lipospheres |
|
|
298 | (1) |
|
Physical Characterization of Lipospheres |
|
|
299 | (3) |
|
Applications of Lipospheres |
|
|
302 | (12) |
|
|
|
314 | (1) |
|
|
|
315 | (2) |
|
Pharmaceutical Aspects of Liposomes: Academic and Industrial Research and Development |
|
|
317 | (28) |
|
|
|
|
|
|
|
317 | (1) |
|
Liposomes: Definition, Needs for, and Outline of their Advantages and Drawbacks |
|
|
318 | (5) |
|
Selection of the Liposome Type/Species: Views and Criteria from Academic and Industrial Research and Their Proposed Integration |
|
|
323 | (3) |
|
Targeted/Modified Liposomes: An Interesting and Exciting Scientific Tool, But Can They Be Made into Products (Especially Immunoliposomes)? |
|
|
326 | (4) |
|
Liposomes as a Sterile, Pyrogen-Free System with Pharmaceutically Acceptable Shelf-Life, Stability, and Dosage Forms |
|
|
330 | (3) |
|
Liposome Characteristics (Percentage of Encapsulation, Kinetics of Release, Biological Activity) In Basic Research and in Quality Assurance |
|
|
333 | (7) |
|
|
|
340 | (1) |
|
|
|
340 | (5) |
|
Microemulsions for Solubilization and Delivery of Nutraceuticals and Drugs |
|
|
345 | (84) |
|
|
|
|
|
|
|
345 | (3) |
|
Microemulsions as Nanovehicles |
|
|
348 | (1) |
|
Part I---Microemulsion Preparation and Microstructures |
|
|
349 | (36) |
|
Part II---Potential Applications |
|
|
385 | (29) |
|
|
|
414 | (2) |
|
|
|
416 | (13) |
|
PART III: APPLICATIONS OF PARTICULATE DELIVERY SYSTEMS |
|
|
|
Self-Emulsifying Oral Lipid-Based Formulations for Improved Delivery of Lipophilic Drugs |
|
|
429 | (52) |
|
|
|
|
|
|
|
|
|
429 | (1) |
|
|
|
430 | (1) |
|
|
|
430 | (3) |
|
|
|
433 | (11) |
|
Characterization of SEDDS |
|
|
444 | (4) |
|
Biopharmaceutical Aspects |
|
|
448 | (18) |
|
The Story of Oral Cyclosporin A |
|
|
466 | (2) |
|
The Oral Paclitaxel Challenge |
|
|
468 | (1) |
|
|
|
469 | (1) |
|
|
|
470 | (11) |
|
Recent Advances in Heparin Delivery |
|
|
481 | (40) |
|
|
|
|
|
|
|
481 | (1) |
|
Blood and Mechanism of Action of Heparins |
|
|
482 | (1) |
|
Evaluation of Heparin Efficiency |
|
|
483 | (1) |
|
Oral Delivery of Heparins |
|
|
483 | (33) |
|
|
|
516 | (1) |
|
|
|
516 | (5) |
|
Particulate Systems for Oral Drug Delivery |
|
|
521 | (42) |
|
|
|
|
|
|
|
521 | (1) |
|
Absorption of Polymeric Particulates from the GI Tract |
|
|
522 | (5) |
|
Use of Polymeric Particles for Oral Administration |
|
|
527 | (25) |
|
|
|
552 | (1) |
|
|
|
553 | (10) |
|
Vesicles as a Tool for Dermal and Transdermal Delivery |
|
|
563 | (24) |
|
|
|
|
|
Dermal and Transdermal Drug Delivery |
|
|
563 | (1) |
|
The Skin Barrier Function |
|
|
564 | (2) |
|
Vesicles as Skin Delivery Systems |
|
|
566 | (6) |
|
|
|
572 | (8) |
|
|
|
580 | (7) |
|
Lipid and Polymeric Colloidal Carriers for Ocular Drug Delivery |
|
|
587 | (38) |
|
|
|
|
|
|
|
587 | (2) |
|
Topically Treated Ocular Pathologies |
|
|
589 | (5) |
|
Lipid and Polymeric Colloidal Carriers: Description and Classification |
|
|
594 | (2) |
|
|
|
596 | (9) |
|
|
|
605 | (2) |
|
|
|
607 | (1) |
|
|
|
608 | (6) |
|
|
|
614 | (3) |
|
Future Directions in Ocular Drug Delivery Using Lipid and Polymeric Colloidal Carriers |
|
|
617 | (1) |
|
|
|
617 | (8) |
|
The Use of Drug-Loaded Nanoparticles in Cancer Chemotherapy |
|
|
625 | (48) |
|
|
|
|
|
|
|
|
|
|
|
|
|
625 | (1) |
|
In Vitro Uptake of NP by Tumoral Cells |
|
|
626 | (13) |
|
Distribution and Pharmacokinetics of Anticancer Drugs Coupled to NP |
|
|
639 | (11) |
|
In Vivo Activity and Toxicity of Anticancer Drugs Coupled to NP |
|
|
650 | (11) |
|
|
|
661 | (1) |
|
|
|
662 | (11) |
|
Development of 5-FU-Loaded PLGA Microparticles for the Treatment of Glioblastoma |
|
|
673 | (16) |
|
|
|
|
|
|
|
|
|
673 | (1) |
|
Microsphere Formulation and Development |
|
|
674 | (4) |
|
|
|
678 | (4) |
|
Application to Glioma Therapy After Tumor Resection: Phase I--II and IIB Studies |
|
|
682 | (2) |
|
Stereotaxic Implantation in Malignant Glioma: Phase I Study |
|
|
684 | (1) |
|
|
|
685 | (1) |
|
|
|
686 | (3) |
|
Nanoparticles as Drug Delivery Systems for the Brain |
|
|
689 | (18) |
|
|
|
|
|
689 | (1) |
|
Drug Delivery to the Brain with Nanoparticles |
|
|
690 | (7) |
|
Long Circulating Nanoparticles for Brain Drug Delivery |
|
|
697 | (2) |
|
Stability of Nanoparticles for Brain Delivery Upon Storage |
|
|
699 | (1) |
|
Mechanism of Nanoparticle-Mediated Drug Transport to the Brain |
|
|
699 | (3) |
|
|
|
702 | (1) |
|
|
|
703 | (4) |
|
Cosmetic Applications of Colloidal Delivery Systems |
|
|
707 | (42) |
|
|
|
|
|
|
|
|
|
|
|
707 | (1) |
|
Types of Vesicular Delivery Systems |
|
|
708 | (7) |
|
|
|
715 | (5) |
|
|
|
720 | (7) |
|
|
|
727 | (4) |
|
|
|
731 | (1) |
|
|
|
732 | (9) |
|
|
|
741 | (1) |
|
|
|
741 | (8) |
| Index |
|
749 | |